A report demonstrated that the blockade of FGF19/FGFR4 pathway significantly sensitizes sorafenib treatment toward HCC.[39] Another study showed that DJ‐1/FGFR1 signaling pathway contributes to sorafenib resistance of HCC whereas FGFR1 affects the survival of sorafenib‐resistant HCC cells through the regulation of molecules involved in tumor apoptosis.[40] In our PDX model, the administration of pan‐FGFR inhibitor Erdafitinib significantly improved the treatment outcome of sorafenib. This evidence concerns the gene PARK7 and hepatocellular carcinoma.